HK Stock Market Move | Jiangsu Hengrui Pharmaceuticals (01276) rose by over 3%, and the application for the market approval of fumarate lincomycin capsules was accepted.
Hengrui Medicine (01276) rose more than 3%, as of the time of publication, rose by 3.24%, to HKD 66.95, with a turnover of HKD 62.8135 million.
Jiangsu Hengrui Pharmaceuticals (01276) rose more than 3%, as of the time of reporting, it increased by 3.24%, reaching HK$66.95, with a turnover of HK$62.8135 million.
In terms of news, Jiangsu Hengrui Pharmaceuticals announced that its subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. recently received a "Acceptance Notice" issued by the National Medical Products Administration for the application for the marketing approval of HRS-5965 Fumarate Liconapane Capsules.
HRS-5965 Fumarate Liconapane Capsules is a complement factor B inhibitor that can inhibit complement-mediated intravascular and extravascular hemolysis reactions, and increase hemoglobin levels. For this indication, there is currently only Novartis' Fabhalta (Iptacopan Hydrochloride) capsule approved for marketing domestically and internationally. According to the EvaluatePharma database, the global sales of this product are expected to be approximately $505 million by 2025. As of now, the total research and development investment in the HRS-5965 Capsule related project is approximately 251.5 million yuan (unaudited).
Related Articles
HK Stock Market Move | NVIDIA GTC leads the way "first stock of Token" XUNCE (03317) soared more than 5% in the morning, the company deeply seizes the value gap of AI data.
CMA LOGISTICS (01292) expects the net profit attributable to the parent company to be approximately 37 to 43 million yuan in 2025, a decrease of about 38.27% to 28.27% year-on-year.
MNSO (09896) spent $233,800 to repurchase 54,700 shares on March 16th.
HK Stock Market Move | NVIDIA GTC leads the way "first stock of Token" XUNCE (03317) soared more than 5% in the morning, the company deeply seizes the value gap of AI data.
CMA LOGISTICS (01292) expects the net profit attributable to the parent company to be approximately 37 to 43 million yuan in 2025, a decrease of about 38.27% to 28.27% year-on-year.
MNSO (09896) spent $233,800 to repurchase 54,700 shares on March 16th.
